70.5 F
Pakistan
Friday, May 1, 2026
HomeHealthMerck Announces First Dose In Phase 3 Study With Enpatoran For Lupus...

Merck Announces First Dose In Phase 3 Study With Enpatoran For Lupus Patients With Active Skin Manifestations – Aetoswir…

(MENAFN – AETOSWire) (BUSINESS WIRE )–Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481 ) and. ..

Read full story on Menafn

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Recent Comments